Intelligence Feed event · Equity · 2026-09-12

    Eli Lilly Immunology Division Reaches $2.6B H1 Sales on 9 Percent Growth

    Question

    Eli Lilly Immunology Division Reaches $2.6B H1 Sales on 9 Percent Growth

    Direct answer

    Eli Lilly disclosed strong execution in its non-incretin portfolio, with the Immunology business delivering $2.6 billion in revenue during the first half of 2026, representing a 9% year-over-year growth rate. The segment currently accounts for 6.1% of Lilly's net sales. While mature products such as Taltz generated core cash flow, newly introduced treatments Ebglyss and Omvoh drove incremental share gains. Management is also integrating assets from the acquisitions of DICE, Morphic, and Merida to construct an oral immunology pipeline.

    Original publisher
    Market Ontology
    Evidence through
    2026-09-12
    Published
    2026-10-20
    Revision
    1 · 2026-10-20

    Cite as: Market Ontology, “Eli Lilly Immunology Division Reaches $2.6B H1 Sales on 9 Percent Growth”, revision 1, evidence through 2026-09-12. https://marketontology.com/market-events/2026-09-12/eli-lilly-immunology-division-reaches-2-6b-h1-sales-on-9-percent-growth-6964fe

    EQUITY
    Eli Lilly Immunology Division Reaches $2.6B H1 Sales on 9 Percent Growth
    Eli Lilly disclosed strong execution in its non-incretin portfolio, with the Immunology business delivering $2.6 billion in revenue during the first half of 2026, representing a 9% year-over-year growth rate. The segment currently accounts for 6.1% of Lilly's net sales. While mature products such as Taltz generated core cash flow, newly introduced treatments Ebglyss and Omvoh drove incremental share gains. Management is also integrating assets from the acquisitions of DICE, Morphic, and Merida to construct an oral immunology pipeline.
    LLYABBV
    Impact
    66
    SEP 12
    SIG
    84%
    LLYABBV
    Eli Lilly Immunology Division Reaches $2.6B H1 Sales on 9 Percent Growth
    Eli Lilly disclosed strong execution in its non-incretin portfolio, with the Immunology business delivering $2.6 billion in revenue during the first half of 2026, representing a 9% year-over-year growth rate. The segment currently accounts for 6.1% of Lilly's net sales. While mature products such as Taltz generated core cash flow, newly introduced treatments Ebglyss and Omvoh drove incremental share gains. Management is also integrating assets from the acquisitions of DICE, Morphic, and Merida to construct an oral immunology pipeline.
    → Expanding immunology revenues diversify Eli Lilly's long-term top-line mix away from singular concentration on GLP-1 obesity franchises.
    Impact
    Eli Lilly disclosed strong execution in its non-incretin portfolio, with the Immunology business delivering $2.6 billion in revenue during the first half of 2026, representing a 9% year-over-year growth rate. The segment currently accounts for 6.1% of Lilly's net sales. While mature products such as Taltz generated core cash flow, newly introduced treatments Ebglyss and Omvoh drove incremental share gains. Management is also integrating assets from the acquisitions of DICE, Morphic, and Merida to construct an oral immunology pipeline.
    Affected
    LLYABBV
    Transmission
    Expanding immunology revenues diversify Eli Lilly's long-term top-line mix away from singular concentration on GLP-1 obesity franchises.

    How this development reaches the affected companies

    AssetExposure and channelDirectionEvidence
    LLYrevenue diversification reducing single-asset concentration discountUp1-3mImmunology revenue up 9% YoY to $2.6B in H1 2026, reaching 6.1% of total corporate revenue.
    ABBVcommercial market share competition in dermatology and inflammatory bowel diseaseWatch1-3mLilly's expansion with Ebglyss and Omvoh competes directly with AbbVie immunology products.

    Does this development affect your holdings?

    Enter your holdings to check them against this and other recent developments, review the decision that matters most, then set a monitor.

    Check this development against my holdings

    Review your initial audit before choosing ongoing portfolio scanning at $79/month.

    What happened next

    Price follow-up pending — no stored daily closes for these assets yet.

    Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.

    No verifiable public source recorded for this card.

    Related

    Check this development against my holdings

    See today's live cards

    Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.

    Open Desk — $399/month